Published in Cancer Weekly, March 21st, 2006
Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave System and associated consumables to perform molecular diagnostic testing for the detection of colorectal and pancreatic cancer from stool samples. NorDiag, in return, will pay a licensing fee and has committed to certain minimum annual purchases.
NorDiag successfully employs the Wave System in its Genefec test, which can detect mutations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.